114 related articles for article (PubMed ID: 10514272)
21. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
22. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
23. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
24. Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus.
Basilico L; Parolaro D; Colleoni M; Costa B; Giagnoni G
Eur J Pharmacol; 1999 Jul; 376(3):265-71. PubMed ID: 10448886
[TBL] [Abstract][Full Text] [Related]
25. L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia.
Rawls SM; Tallarida RJ; Gray AM; Geller EB; Adler MW
J Pharmacol Exp Ther; 2004 Feb; 308(2):780-6. PubMed ID: 14610231
[TBL] [Abstract][Full Text] [Related]
26. delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
Burkey TH; Quock RM; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Apr; 323(2-3):R3-4. PubMed ID: 9128853
[TBL] [Abstract][Full Text] [Related]
27. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
Smith SR; Terminelli C; Denhardt G
Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577
[TBL] [Abstract][Full Text] [Related]
28. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
29. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models.
Smith SR; Denhardt G; Terminelli C
Eur J Pharmacol; 2001 Nov; 432(1):107-19. PubMed ID: 11734194
[TBL] [Abstract][Full Text] [Related]
30. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
Landi M; Croci T; Rinaldi-Carmona M; Maffrand JP; Le Fur G; Manara L
Eur J Pharmacol; 2002 Aug; 450(1):77-83. PubMed ID: 12176112
[TBL] [Abstract][Full Text] [Related]
31. N-methyl-D-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia.
Rawls SM; Cowan A; Tallarida RJ; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Oct; 303(1):395-402. PubMed ID: 12235276
[TBL] [Abstract][Full Text] [Related]
32. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles.
Jansen EM; Haycock DA; Ward SJ; Seybold VS
Brain Res; 1992 Mar; 575(1):93-102. PubMed ID: 1504787
[TBL] [Abstract][Full Text] [Related]
33. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes.
Kaplan BL; Rockwell CE; Kaminski NE
J Pharmacol Exp Ther; 2003 Sep; 306(3):1077-85. PubMed ID: 12805480
[TBL] [Abstract][Full Text] [Related]
34. A role of nitric oxide in WIN 55,212-2 tolerance in mice.
Spina E; Trovati A; Parolaro D; Giagnoni G
Eur J Pharmacol; 1998 Feb; 343(2-3):157-63. PubMed ID: 9570463
[TBL] [Abstract][Full Text] [Related]
35. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus.
Miller AS; Walker JM
Eur J Pharmacol; 1996 May; 304(1-3):29-35. PubMed ID: 8813581
[TBL] [Abstract][Full Text] [Related]
36. Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure.
Hoffman AF; Oz M; Caulder T; Lupica CR
J Neurosci; 2003 Jun; 23(12):4815-20. PubMed ID: 12832502
[TBL] [Abstract][Full Text] [Related]
37. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
[TBL] [Abstract][Full Text] [Related]
38. Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea-pig trachea.
Nieri P; Martinotti E; Testai L; Martinelli C; Breschi MC
Eur J Pharmacol; 2003 Aug; 475(1-3):115-8. PubMed ID: 12954367
[TBL] [Abstract][Full Text] [Related]
39. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
40. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus.
Blair RE; Deshpande LS; Sombati S; Falenski KW; Martin BR; DeLorenzo RJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1072-8. PubMed ID: 16469864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
